



ASX RELEASE (21 JANUARY 2020)

## **TGA GMP Manufacturing Licence Granted for Southport Facility** **Complete pathway to revenue from medicinal cannabis medicines production in 2020**

### **Key Points:**

- Internationally recognised GMP Licence authorises manufacture, packaging, and laboratory testing of medicinal cannabis
- The Southport Facility, a European designed and built pharmaceutical bio-floral extraction facility, meets key requirements for entering the European market
- THC Global adds imported crude to locally grown cannabis to accelerate medicine availability and ensure full scale-up capability
- Production of medicines commenced under newly appointed THC Pharma Chief Operating Officer

THC Global Group Limited (**THC Global** or the **Company**) (ASX:THC) is pleased to advise that the Australian Therapeutic Goods Administration (**TGA**) has granted the Company a Licence to Manufacture Therapeutic Goods for the Southport Facility, more commonly known as a **GMP Licence**, completing all licences required for THC Global to commence commercial manufacture of medicinal cannabis.

A GMP Licence is a mandatory requirement for the commercial manufacture of medicinal cannabis in Australia, and is mutually recognised for supply of pharmaceutical goods in 29 countries across Europe, Asia and North America (Canada). The GMP Licence authorises the Company to manufacture: Active Pharmaceutical Ingredient (API) extracts; formulation and packaging of medicines; on-site testing and analysis; and supply of medicinal cannabis for human trials in Australia and globally.

The Company's Southport Facility is the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere and is one of the world's largest pharmaceutical GMP licenced facilities for the manufacture of medicinal cannabis. With the receipt of the GMP Licence, THC Global will now seek to complete negotiations for the export supply of cannabis medicines. The European design and equipment origin of the Southport facility meets key requirements for entering the rapidly expanding European market, differentiating THC Global from almost all established cannabis companies internationally.

On 2 January 2020, the Office of Drug Control clarified that appropriately licensed and permitted organisations may import cannabis material, including extracts, for use in manufacture. THC Global will utilise Australian grown cannabis and imported crude extract to accelerate its timeline for local manufacture. The approach will ensure THC Global can scale towards full site capacity as it increases domestic and international market reach.

Production of medicines has commenced under the oversight of newly appointed Chief Operating Officer of THC Pharma, Angela Macquire. Angela's significant experience in the pharmaceuticals industry at various senior-executive levels, and direct experience in medicinal cannabis formulation and Australian clinical trials, will be of significant benefit to the Company as production volumes continue to grow through 2020.

THC Global Chief Executive Officer, Ken Charteris, commented:

"THC Global has now received a pharmaceutical GMP licence issued by a government authority, which remains a rarity in the cannabis world. We anticipate near-term completions of commercial negotiations with multiple parties interested in our scalability, quality of production and ability to compete on price globally."





Above: THC Global's medicinal cannabis manufacturing team at the Southport Facility following the grant of the Company's TGA Manufacturing Licence on 20 January 2020.

**For further information, please contact:**



**Ken Charteris**  
Chief Executive Officer  
e: [ceo@thc.global](mailto:ceo@thc.global)

**Henry Kinstlinger**  
Company Secretary  
e: [corporate@thc.global](mailto:corporate@thc.global)  
p: +61 2 8644 0601

**Sonny Didugu**  
Investors & Media  
e: [media@thc.global](mailto:media@thc.global)  
p: +61 2 8088 4760

**THC Global Group Limited (ASX: THC) [thc.global](http://thc.global)**

THC Global operates under a 'Farm to Pharma' pharmaceutical model, now holding all three key cannabis licences being a Cannabis Research Licence, a Medicinal Cannabis Licence (Cultivation), and two Manufacture Licences through its domestic medicinal cannabis subsidiaries THC Pharma and Candeo. THC Global's main facility, the Southport Manufacturing Facility is the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere. The Southport Facility is licenced and permitted, including holding Schedule 8 controlled substances and Schedule 4 pharmacy medicines licences.

THC Global is in prime position to commence medicinal cannabis production to service both domestic patients and the global export market. In addition to its core Australian medicinal cannabis assets, THC Global has a significant Canadian presence. THC Global's hydroponics equipment division, Crystal Mountain, is a revenue generating manufacturer, wholesaler, and retailer of hydroponics equipment and supplies for cannabis cultivation. THC Global also owns Candeo Canada, a holder of property in Nova Scotia, Canada being developed into a large scale cannabis production site.